✻ Life Science and Pharmaceuticals Science ✻
On Wednesday, November 18, 2020 at 06:59 Pfizer published its website a short summary about a common study with BioNTech on Phase 3 Study of COVID-19 Vaccine Candidate. According to published article of Pfizer on its website, primary efficacy analysis demonstrates 95% effectiveness against COVID-19.
Pursuant to the release, efficacy was consistent and stable across age, gender race and ethnicity demographics; the observed efficacy of vaccine candidate in adults over 65 years of age was over 94%. Safety data milestone required by U.S. Food and Drug Administration (FDA) has been achieved which is necessary for Emergency Use Authorization (EUA).
Pursuant to the release, data demonstrate that the vaccine was well tolerated across all populations with over 43.000 participants enrolled. Pfizer did not observe serious safety concerns and the scrutiny indicated adverse events (side effects) in frequency of fatigue (at the level 3.8%) and headache (at the level 2.0%). Pfizer and BioNTech expect to produce the vaccine against COVID-19 globally 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021. The two company also confident that the vaccine will be distributed around the world easily.
During the trial they observed 10 severe cases of COVID-19. They also performed data analysis in the trial. In addition to this the scrutiny has progressed well, it was determined that the vaccine is capable to put an end to this devastating pandemic. Therefore Pfizer and BioNTech would like to submit a request within few days to the FDA for an EUA based on the totality of safety and efficiency data collected to date.
The experts of Pfizer and BioNTech expressed their hope that these vaccines will give solution quickly and efficiently to overcome this devastating pandemic period. According to the forecasts, the vaccines will be issued urgently in the next year by the summer to the world.
If you would like to read more about this topic, please visit the website of the Pfizer.
|Source of this article||https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine#.X7meeHk1QgI.linkedin|
|Press release of Pfizer||https://www.businesswire.com/news/home/20201118005595/en/|